tein 1 (ab2GP1) antibodies have been reported in untreated HIV-infected men; aCL prevalence has ranged from 36% to 67% [4] [5] [6] [7] . Other autoantibodies, including anti-DNA, antinuclear, and organ-specific antibodies, have been reported [4, 8] , but the exact frequency of autoimmune manifestations and their pathogenesis during HIV infection remain unknown.
Hypotheses proposed to explain these manifestations include cross-reactivity between pathogens and self-proteins [1] , immune activation [9] , molecular mimicry [10, 11] , and a direct effect of HIV on endothelial, synovial, and other hematopoietic cells [8, 12] . In addition to the usual T cell activation assessed by HLA-DR and CD38 expression, B cell activation is reported during HIV infection; this is frequently assessed by measuring soluble CD23, a low-affinity IgE receptor on B cells that is used as a B cell activation marker in lymphoproliferative disorders [13] . This immune activation has not been related to increased autoantibody levels in HIV infection.
Haynes et al. [1] have demonstrated that 2F5 and 4E10, which are 2 neutralizing antibodies directed against epitopes of the membrane proximal external region (MPER) of gp41 [14, 15] , act in vitro as polyspecific autoantibodies that are reactive with cardiolipin, an endogenous phospholipid. Together with 2G12 and b12 (which are 2 other monoclonal neutralizing antibodies), 2F5 and 4E10 are among the very few antibodies generated to date from patients with HIV infection [16] . Their reactivity to cardiolipin, which is perhaps explained by autoantigen mimicry, raises safety concerns about passive immunotherapy with these monoclonal antibodies.
Although neutralizing antibodies are rare among most HIVinfected patients, they are reported more frequently among that subset of HIV-infected patients with long-term nonprogression to HIV disease [17] [18] [19] . Our group recently developed competitive and noncompetitive ELISAs to measure antibodies directed against major conserved epitopes involved in neutralization (2G12, 2F5, 4E10, and b12) in serum samples obtained from 67 patients with long-term nonprogression or slow progression to HIV disease in the French Asymptomatiques à Long Terme (ALT ANRS CO15) cohort (the SP group) [20, 21] . The 2G12-like and 2F5-like antibodies were detected in serum samples obtained from almost all of the patients in this cohort, and 60% of the samples were reactive against the MPER of gp41 (covering both the 2F5 and 4E10 epitopes) [20] .
These observations raised the question of whether autoantibodies, especially aCL, are present in the serum of this subset of patients with well-characterized antibodies and viral parameters. Therefore, we investigated in vivo whether aCL is related to neutralizing antibodies reacting with 2F5 and 4E10 epitopes. Autoantibodies were measured in serum samples obtained from ALT ANRS CO15 cohort members and were correlated with neutralizing antibodies and with immune, virological, and clinical characteristics. The same tests were performed with control serum samples obtained from 50 patients with chronic infection and disease progression (the P group).
PATIENTS, MATERIALS, AND METHODS

Patients.
We studied 67 patients from the ALT ANRS CO15 cohort who had slow progression of HIV disease (the SP group) [22] . Inclusion criteria included an 8-year history of HIV seropositivity, a 5-year history of CD4 + cell counts 1600 cells/ mL, a lack of clinical symptoms, and no history of antiretroviral therapy [22] . Plasma viral load, which was not routinely available at inclusion (during the period 1994-1995), was not a selection criterion. The institutional review board of Pitié-Salpêtrière Hospital (Paris, France) approved the study protocol, and each patient provided written informed consent. Serum samples obtained from all patients in the SP group in whom neutralizing antibodies had previously been identified were tested [20, 21] .
For comparison, 50 consecutive adult patients with chronic HIV infection and standard disease progression who were hospitalized in the Department of Infectious Diseases of the Pitié-Salpêtrière Hospital were prospectively recruited (the P group). All control patients provided written informed consent.
Autoantibody measurements. To determine autoantibody measurements for the 67 patients in the SP group, all antibodies were analyzed from frozen serum samples that had been collected during the year of cohort entry. When aCL was detected, a second measurement was performed using a serum sample obtained 1 year after the year of cohort entry, as recommended [23] . Fresh serum samples obtained from the 50 patients in the P group were screened only for aCL, ab2GP1, and antinuclear antibodies. aCL antibody levels were measured for aCL IgG and IgM isotypes with use of ELISA (CardioLisa; BioMedicalDiagnostic). IgG or IgM levels of 115 U/L were considered to be positive [24] .
ab2GP1 IgG and IgM isotypes were measured with an inhouse ELISA, according to published recommendations [23] . Samples were considered to be positive when ab2GP1 IgG isotopes were 10.16 optical density units (ODU) and ab2GP1 IgM isotopes were 10.200 ODU.
Antinuclear antibody immunofluorescence was tested on HEp-2000 cells (Immunoconcepts). Titers of у1:160 were considered to be positive. The nuclear fluorescence patterns were described as homogeneous, speckled, mixed, nucleolar, or other, and the cytoplasmic patterns were described as diffuse, granular, or filamentous.
Anti-double-stranded DNA antibodies were tested for by ELISA (ETI-dsDNA; Dia-Sorin). Antibody levels 128 IU/mL were graded as positive. Antinucleosome antibodies were detected with an ELISA that was developed in-house, as described elsewhere [25] . To determine anti-extractable nuclear antigen (ENA) antibody levels, each sample underwent a multiplexed microparticle-based Luminex immunoassay for antibodies to nuclear antigens (AtheNA Multi-Lyte). Titers 1120 U/mL were considered to be positive and were confirmed by a second Luminex assay (FIDIS; BioMedical Diagnostics) to detect discrepancies.
Antibodies to neutralizing epitopes. Competitive and noncompetitive ELISAs were previously developed to detect and titrate levels of antibodies against major epitopes known to be involved in broad neutralization: 2F5-like, 4E10-like, b12-like, or 2G12-like antibodies [20] . MPER antibodies were detected and quantified by an indirect peptide ELISA, with the synthetic peptide NEQELLELDKWASLWNWFNITN (MPER peptide), which covers the 2F5 and 4E10 epitopes [20] .
Competition between MPER peptide and aCL activity. To evaluate whether the MPER could inhibit aCL activity, we tested all aCL-positive serum samples with use of increasing amounts of the MPER peptide to block aCL activity. Peptide concentrations of 1, 10, 100, 250, 500, and 1000 mg/mL were used for each aCL-positive sample were incubated for 30 min at room temperature with the diluted serum samples. We determined aCL activity at each concentration with the ELISA test described above. Results were expressed as ODU at 405 nm.
Measurement of T and B cell activation.
Parameters of T cell immune activation were measured by flow cytometry on cryopreserved PBMCs. In brief, cells were stained with the following monoclonal antibodies: anti-CD3-fluorescein isothiocyanate, anti-CD4-allophycocyanin, anti-CD8-phycoerythrin indotricarbocyanine (Becton Dickinson), all combined with anti-CD71-phycoerythrin or anti-CD38-phycoerythrin and anti-DR-phycoerythrin. Data were acquired using flow cytometery (FACScalibur; Becton Dickinson). At least 30,000 events in the lymphocyte gate were recorded, and CD38 and CD71 expression was analyzed within the CD8 + cell and CD4 + cell gated populations, respectively. Data were analyzed with CellQuest software (Becton Dickinson).
B cell activation was determined by quantifying soluble CD23 with use of ELISA (human soluble CD23 CD23/Fce RII, Quantikine; R&D Systems) in the 64 available serum samples. Results were expressed in pg/mL and were considered to be positive when they exceeded the mean plus 2 SDs of normal values (268 pg/mL).
Statistical analysis. Differences between the SP group and the P group were assessed using the x 2 test for categorical variables and the Mann-Whitney U test for continuous variables. Associations between continuous variables were assessed using the nonparametric Spearman's correlation coefficient test. + cells, and soluble CD23 levels were analyzed as continuous variables. The categorical variables were transmission group and sex. Only variables with a P value !.20 in the univariate analysis were retained in the multivariable backward analysis; was P ! .05 considered to be statistically significant. Data were analyzed using SAS, version 9.1 (SAS Institute).
RESULTS
Demographic characteristics.
The demographic, virologic, and immunologic characteristics of the 67 untreated patients in the SP group are described in table 1. Patients were mostly men (78%), with a median age of 37 years (range, 22-65 years), a median CD4 + cell count of 679 cells/mL (range, 278-1286 cells/mL), and an HIV RNA load of 6200 copies/mL (range, 20-860,000 copies/mL). None of the patients had other infections or autoimmune disorders, with the exception of 28 of the 64 tested patients who were coinfected with hepatitis C virus.
The 50 patients in the P group (table 1) were also mostly men (76%). Their median age was 43 years (range, 18-69 years), their median CD4 + cell count was 202 cells/mL (range, 0-1149 cells/mL), and their median HIV RNA load was 2265 copies/mL (range, 40-1,399,655 copies/mL). Thirty-one (62%) of these patients were receiving HAART, and 10 had hepatitis C virus coinfection. Autoantibodies in the SP group. At enrollment, serum aCL At entry, only 3 (9%) of the 33 aCL-positive patients were also positive for ab2GP1 IgG (median IgG level, 0.197 ODU; range, 0.19-0.375 ODU), and none were positive for IgM. None of the 34 aCL-negative patients had ab2GP1. Antinuclear autoantibodies were detected in 20 (30%) of 67 patients; patterns of nuclear fluorescence were speckled (16 patients), homogeneous (5 patients), nucleolar (3 patients), and mixed (5 patients). More aCL-positive patients than aCL-negative patients had antinuclear autoantibodies (11 vs. 9 patients;
). P p .004 Anticytoplasmic autoantibodies were detected in 13 (19%) of 67 patients, with filamentous (9 patients), diffuse (2 patients), and granular patterns (2 patients). Anticytoplasmic autoantibodies were detected in 7 aCL-positive patients and 6 aCL-negative patients. The difference between these frequencies was not statistically significant.
In 19 (28%) of 67 patients, anti-ENA autoantibodies were positive for у1 of 5 specificities: histone (12 patients), SSA (4), SSB (1), Sm (2), RNP (7), Scl70 (1), or centromere (2). Anti-ENA autoantibodies were detected in 13 (39%) of 33 aCLpositive patients and in 6 (18%) of 34 aCL-negative patients; the difference between these frequencies was not statistically significant. These results were independently obtained with the 2 multiplexed immunoassays. As shown in table 3, 10 (30%) of 33 aCL-positive patients had only aCL, 14 (42%) had 1 other autoantibody specificity, 8 (24%) had 2 other autoantibody specificities, and 1 (3%) had 3 autoantibody specificities.
aCL and ab2GP1 in the P group. Of 50 patients in the P group, 29 (58%) had detectable aCL IgG isotypes, with a median IgG level of 27 U/L (range, 18-48 U/L). Seven patients (14%) had aCL IgM (median IgM level, 23 U/L; range, 15-45 U/L); 6 of these patients also had detectable aCL IgG. There did not appear to be a statistically significant difference in aCL IgG levels between the SP group and the P group.
Four aCL-positive patients had ab2GP1 IgG (median IgG At aCL detection, 10 (20%) of 50 patients in the P group had a history of or current deep venous thrombosis (7 patients) or pulmonary embolism (5). Four patients had results that were positive for aCL IgG (median IgG level, 27 U/L; range, 18-48 U/L). Past or current thrombosis was present in 4 (14%) of 29 aCL-positive patients and 6 (19%) of 31 aCL-negative patients. Thrombosis was not significantly associated with aCL positivity or aCL IgG levels in the P group. Two of the 50 patients also had quiescent systemic lupus erythematosus, which was treated with corticosteroids (!10 mg/day).
Correlation between autoantibody specificities and disease parameters. In the SP group, aCL was associated with higher loads of HIV RNA and DNA ( figure 1A and 1B) . Median RNA loads were 36,000 copies/mL (range, 36-860,000 copies/mL) in aCL-positive patients and 520 copies/mL (range, 20-280,000 copies/mL) in aCL-negative patients ( ); median DNA P ! .001 loads were 663 copies/mL (range, 8-15,854 copies/mL) and 63 copies/mL (range, 2-9635 copies/mL), respectively ( ). P ! .001 Moreover, aCL antibody levels were significantly correlated with RNA ( ; ) and DNA loads ( ; r p 0.486 P ! .001 r p 0.516 P ! ) ( figure 1A and 1B) . Similarly, anti-ENA antibodies were .001 associated with high RNA ( ) and DNA loads ( P p .005 P p ), whereas cytoplasmic antibodies were associated only with .002 high RNA load ( ). P p .01 In the P group, the median HIV RNA load was modestly but statistically significantly higher in aCL-positive patients than in aCL-negative patients (520 copies/mL [range, 20-280,000 copies/mL] vs. 200 copies/mL [range, 40-750,000 copies/mL];
). aCL antibody levels also had a statistically P p .01 significant correlation with RNA levels ( ; ). r p 0.389 P p .012 Similar results were observed for all patients (in both the SP and P groups) for RNA loads ( ; ) (figure 1C r p 0.440 P ! .001 and 1D). Similarly, aCL antibodies were associated with the absence of HAART ( Correlation between autoantibody specificities and anti- bodies directed against conserved epitopes involved in broad neutralization. We analyzed the correlation between autoantibodies and antibodies to several major HIV epitopes previously identified in the SP group [20] . Competitive ELISA showed that, among the 67 patients in the SP group, the median levels of 2F5-like antibodies were significantly higher in aCLpositive patients than in aCL-negative patients (9. ). In contrast, no P p .01 association was found between these anti-HIV specificities and any other autoantibodies. Detection of b12-like antibodies was associated with both aCL ( ) and anticytoplasmic anti-P p .01 bodies (
), but detection of 2G12-like antibodies was P p .01 associated with no autoantibodies.
Next, we conducted inhibitory experiments in which the MPER peptide was added to the aCL assay for the 28 aCLpositive members of the SP group for whom serum samples were available. We observed a slight decrease in aCL activity in only 3 patients (not shown).
Multivariate analysis. A multivariate analysis of the SP group was conducted (table 4). Only 3 factors were independently associated with an increased risk of detecting aCL: the presence of MPER antibodies (OR, 1.8; 95% CI, 1. ). RNA load was P p .02 not associated with this risk.
A multivariate analysis of the P group was conducted (table  5) . Only HAART was independently associated with a decreased risk of detecting aCL (OR, 0.14; 95% CI, 0.03-0.56; P p ). .006
DISCUSSION
In this study, aCL was observed in both the P group and the SP group; in the latter, it was associated with antibodies to the HIV MPER and with viral load and immune activation. The frequency of these antibodies among HIV-infected patients was much higher than that reported among older, healthy populations, among whom frequencies ranged from !1% to 5% [27] . It also appears to have been higher than the frequencies reported among patients with other infectious diseases, for whom the prevalence has ranged from 6% to 37% [28] [29] [30] . Even for patients with autoimmune disorders (in particular, lupus erythematosus), the prevalence of aCL IgG is only 24%, which is lower than that reported among patients with HIV infection [31, 32] . Frequencies of these and similar antibodies among HIV-infected patients ranged from 36% to 67% before the introduction of HAART [5] [6] [7] .
Detection of aCL was not associated with any clinical features of antiphospholipid syndrome in our study, for reasons that remain unclear [33] . Thrombotic complications have not been reported after passive immunotherapy with 2F5 and 4E10 [34] . Note that aCL may appear many years before autoimmune connective tissue disease is diagnosed [35] . aCL in infectious diseases is usually described as natural rather than pathogenic, and the enhancement of aCL binding by b2GP1 is considered to be a marker that distinguishes autoimmune aCL from aCL associated with infection [36] . In our study, aCL did not bind b2GP1 and probably reflects persistent humoral responses, rather than any pathogenic role.
To attempt to understand the high prevalence of aCL among patients with HIV infection, we tested its association with disease characteristics. In the 2 groups that we studied, the presence and level of aCL were correlated with HIV parameters. These findings suggest that control of HIV replicationwhether spontaneous or after receipt of antiretroviral therapyis associated with lower production of aCL antibodies. These data are consistent with the reduction in frequency of autoimmune disorders with clinical manifestations since the introduction of HAART [37, 38] .
We also tested whether the high prevalence of autoantibodies might result from polyclonal immune activation secondary to ongoing HIV replication and found that aCL correlated well with the levels of activated CD4 + and B cells. In contrast, we found no correlation with the titers of activated CD8 + T cells [39, 40] , which are known to be associated with viral load [41] [42] [43] . These correlations strengthen the hypothesis that antibody production in HIV infection may reflect dysregulation of the CD4 + and B cell network, independent of the plasma viral load. Finally, our study was designed to test the association of aCL with antibodies to various major neutralizing epitopes. Haynes et al. [1] showed in vitro aCL reactivity for 2F5 and 4E10 monoclonal antibodies. Both 2F5 and 4E10 monoclonal antibodies recognize 2 adjacent and highly conserved contiguous epitopes in the HIV-1 envelope gp41 MPER [44] , which plays an essential role in the cell fusion machinery and in virus infectivity [45, 46] . We demonstrated an association between MPER antibodies and aCL in serum samples obtained from patients in the SP group, but we found no such association for 2G12-and b12-like antibodies. Our data thus confirm, to our knowledge for the first time, the in vivo association between MPER antibodies and aCL.
Considered together with the findings by Haynes et al. [1] , our data suggest that HIV may have evolved cardiolipin-emulating MPER epitopes. This association was independent of both viral load and immune activation. Recent studies have revealed that the 2F5-cardiolipin recognition mechanism is independent of membrane partitioning and involves the epitope binding site [47] . Others argue that the lipid environment plays a major role [48] , especially for the 4E10 peptide [49] . Competition with the MPER peptide blocked cardiolipin reactivity in only 11% of our cases, suggesting that cardiolipin antibodies may react with antigenic determinants that probably differ from the MPER sequence.
Taken together, our findings demonstrate that aCL antibodies are frequently detected in HIV-infected patients and are strongly and independently linked with levels of virus replication, regardless of disease stage; with CD4 + T and B cell activation; and with HIV antibodies to the MPER. These data require longitudinal evaluation before we can reach a conclusion about the exact role of such autoantibodies during HIV infection and elucidate the links between MPER antibodies and aCL activity in the serum of HIV-infected patients.
